Fibroblast growth factor - 21 as a novel marker up-regulated in type 2 diabetes?

Monika Lenart-Lipińska; Beata Matuszek; Dariusz Duma; Iwona Kaznowska-Bystryk; Beata Wojtysiak-Duma; Andrzej Nowakowski; Janusz Solski

doi:10.12923/

Authors

Monika Lenart-Lipińska Chair and Department of Laboratory Diagnostics Author https://orcid.org/0000-0002-3418-6830
Beata Matuszek Chair and Department of Endocrinology Author https://orcid.org/0000-0001-7386-8087
Dariusz Duma Chair and Department of Laboratory Diagnostics Author https://orcid.org/0000-0002-5844-9033
Iwona Kaznowska-Bystryk Chair and Department of Laboratory Diagnostics Author https://orcid.org/0000-0002-9325-9753
Beata Wojtysiak-Duma Department of Biochemical Diagnostics, Medical University of Lublin Author https://orcid.org/0000-0002-2544-1385
Andrzej Nowakowski Chair and Department of Endocrinology Author
Janusz Solski Chair and Department of Laboratory Diagnostics Author https://orcid.org/0000-0003-2884-1509

DOI:

https://doi.org/10.12923/

Keywords:

FGF-21, type 2 diabetes, insulin resistance, adiponectin, adipocytokines

Abstract

Numerous animal studies suggest that FGF-21, a newly discovered adipocytokine, is a potent metabolic regulator with multiple beneficial effects on insulin resistance state. The aim of the study was assessment of FGF-21 concentrations in the serum of patients with type 2 diabetes and evaluation of possible relationships between the studied adipocytokine and selected clinical and biochemical parameters. The study was conducted in 64 patients with type 2 diabetes, 34 women and 30 men aged 47–72 with the mean duration of diabetes 10,9 ±8,2 years. In fasting serum samples concentrations of glucose, insulin, lipids profile parameters, creatinine, CRP, fibrinogen, HbA1C, adiponectin and FGF-21 were determined at the time of admission to the Department of Endocrinology and after 2 years of follow-up. The control group comprised 20 healthy persons matched for age to the study group, with no disturbances in carbohydrate metabolism, 14 women and 8 men. Results: In patients with diabetes the mean FGF-21 concentration was 331,94 pg/ml and was significantly greater in comparison to the control group: 158,11 pg/ml, p<0,01. After 2 years of follow-up the mean FGF- 21 concentration was 271,3 pg/ml. Significant correlations between FGF-21 concentrations and adiponectin (r=-0,24, p<0,05), weight (r=0,27, p<0,05), glucose (r=0,27, p<0.05), HDL (r=-0,26, p<0.05), TG (r=0,27, p<005) and eGFR (r=- 0,28, p<0,05) were observed. Conclusions: On the basis of the conducted studies it can be concluded that greater FGF-21 concentration observed in the examined group of patients with type 2 diabetes may result from compensatory reaction to metabolic disturbances or tissue resistance to this adipocytokine. Changes in parameters of metabolic control of diabetes are not connected with changes of FGF-21 concentrations.

References

1. Chen W.W., Li L., Yang G.Y. et al.: Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes, 116, 65, 2008.

2. Dostalova I., Kavalkova P., Haluzikova D. et al.: Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J. Clin. Endocrinol. Metab., 93, 3627, 2008.

3. Goetz R., Beenken A., Ibrahimi O.A. et al.: Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell Biol., 27, 3417, 2007.

4. Inagaki T., Dutchak P., Zhao G. et al.: Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab., 5, 415, 2007.

5. Kharitonenkov A., Shanafelt A.B.: FGF21: a novel prospect for the treatment of metabolic diseases. Curr. Opin. Investig. Drugs., 10, 359, Apr 2009.

6. Kharitonenkov A., Shiyanova T.L., Koester A. et al.: FGF-21 as a novel metabolic regulator. J. Clin. Invest., 115, 1627, 2005.

7. Kharitonenkov A., Wroblewski V.J., Koester A. et al.: The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology, 148, 774, 2007.

8. Stein S., Bachmann A., Lössner U. et al.: Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care, 32, 126, 2009.

9. Takemura Y., Walsh K., Ouchi N.: Adiponectin and cardiovascular inflammatory responses. Curr Atheroscler. Rep., 9, 238, 2007.

10. Wang H., Qiang L., Farmer S.R.: Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol. Cell Biol., 28, 188, 2008.

11. Wente W., Efanov A.M., Brenner M. et al.: Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes, 55, 2470, 2006.

12. Zhang X., Yeung D.C., Karpisek M. et al.: Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes, 57, 1246, 2008.

Fibroblast growth factor - 21 as a novel marker up-regulated in type 2 diabetes?

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

Issue

Section

License

sidebar

Language